Future therapies in hormone-refractory prostate cancer

Matthew R. Smith, Joel B. Nelson, Robert S. DiPaola, Michael A. Carducci, Ian M. Thompson

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression. Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. To alter the currently inevitable progression of HRPC to death, new targets and new therapies are needed. This article reviews investigational therapies directed against standard targets (eg, the hypothalamic-pituitary-gonadal axis) as well as novel targets (eg, the endothelin axis).

Original languageEnglish
Pages (from-to)9-17
Number of pages9
Issue number5 SUPPL.
StatePublished - May 2005

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Future therapies in hormone-refractory prostate cancer'. Together they form a unique fingerprint.

Cite this